melanoma peptide-pulsed dendritic cells
Vaccineexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 1999 (NCT00243594)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
- autologous melanoma lysate-pulsed autologous dendritic cell vaccine
- dendritic cells loaded with malignant melanoma
- melanoma peptide-pulsed dendritic cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00107159 | Phase 2 | Jan 1, 2005 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT01082198 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2002 | Maria Sklodowska Curie Children's Hospital |
| NCT01278940 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2002 | Osaka University, University of Oslo |
| NCT00243594 | Phase 1/Phase 2 (Phase 2) | Sep 1, 1999 | Dutch Cancer Society, Radboud University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dutch Cancer Society | Academic/Hospital | 1 | 0 | 1 | 1999 |
| Maria Sklodowska Curie Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2005 |
| Osaka University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2005 |
| University of Oslo | Academic/Hospital | 1 | 0 | 1 | 2002 |
7 organizations
Page 1 / 1